REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
- Positive interim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202
- Robust microdystrophin expression observed in patients
- Evidence of strength and motor function improvement noted
- Encouraging safety data with no drug-related serious adverse events
- Plans to initiate pivotal trial in the second half of 2024
- None.
The preliminary results from the Phase I/II AFFINITY DUCHENNE trial for RGX-202, a gene therapy product for Duchenne muscular dystrophy (DMD), indicate a significant increase in microdystrophin expression levels in patients, particularly in the cohort receiving the higher dose. Microdystrophin is a truncated version of the dystrophin protein, which individuals with DMD lack due to genetic mutations. The surrogate endpoint of microdystrophin expression is critical because it serves as an indicator of the therapeutic's potential efficacy. The reported 75.7% expression level compared to a normal control is promising, as it suggests a dose-dependent relationship that could be pivotal in determining the optimal dose for future trials.
Moreover, the reduction in serum creatine kinase (CK) levels, a biomarker for muscle damage, further supports the potential for clinical improvement. Typically, DMD patients exhibit elevated CK levels due to ongoing muscle damage. A 77% reduction at ten weeks post-administration is noteworthy as it implies a decrease in muscle injury, which may correlate with the observed improvements in strength and motor function.
These early findings are vital as they could influence the design of the pivotal trial and the subsequent Biologics License Application (BLA) filing. The use of RGX-202 microdystrophin expression as a surrogate endpoint aligns with the FDA's accelerated approval pathway, which can expedite treatments for serious conditions with unmet medical needs. However, long-term data on durability and functional outcomes are essential to confirm the therapy's efficacy and safety profile.
REGENXBIO's announcement of interim data from its Phase I/II trial has potential implications for its stock performance and investor sentiment. The positive safety profile, with no drug-related serious adverse events reported, is crucial for investor confidence, especially in the high-risk biotechnology sector. The early efficacy signals, including robust microdystrophin expression and functional improvements, could be a catalyst for the company's valuation if these results translate into a successful pivotal trial and eventual product approval.
The company's timeline for pivotal dose determination and trial initiation in the second half of 2024 is an important milestone to monitor. Investors will likely scrutinize the strength and functional assessment data to be shared later this year, as these will offer more substantial evidence of RGX-202's potential commercial viability. The decision to use microdystrophin expression as a surrogate endpoint could streamline the regulatory process, but it also places significant emphasis on the correlation between this biomarker and meaningful clinical outcomes. Financially, REGENXBIO must manage its cash burn rate and secure sufficient funding to complete its clinical development and potential commercialization phases, which are critical factors that affect stock liquidity and investor interest.
The regulatory landscape for gene therapies like RGX-202 is evolving, with the FDA providing pathways for accelerated approval based on surrogate endpoints. REGENXBIO's strategy to use microdystrophin expression as a surrogate endpoint is aligned with this regulatory framework, potentially reducing the time to market for RGX-202 if the pivotal trial confirms these early results. However, the regulatory approval process for gene therapies remains stringent, with the FDA requiring robust evidence of safety and efficacy. The agency will likely scrutinize the long-term impact of RGX-202, including potential immunogenicity and durability of microdystrophin expression.
Furthermore, the trial design incorporates feedback from the Duchenne community and key opinion leaders, which may facilitate patient recruitment and engagement—a factor that can positively influence the speed and success of clinical trials. The inclusion criteria based on specific DMD gene mutations and comprehensive immunosuppression regimens demonstrate a tailored approach to addressing the complex nature of DMD and the body's immune response to gene therapies. The focus on patient-centric endpoints like the North Star Ambulatory Assessment (NSAA) and timed function tests will be critical for demonstrating real-world benefits and supporting the therapy's value proposition to regulators, payers and patients.
- New three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expression
- Patient aged 12 years at dosing had expression level at
75.7% of control
- Patient aged 12 years at dosing had expression level at
- Early evidence of strength and motor function improvement observed
- On track to initiate pivotal trial in second half of 2024
- Webcast this morning, Tuesday, March 5, 8:30 a.m. ET, with principal investigator
"RGX-202 at dose level 2 is demonstrating significantly increased microdystrophin expression in a 12-year-old patient," said Kenneth T. Mills, President and CEO, REGENXBIO. "We know there is an insufficient level of data available to the community for boys older than 7 years, and we are committed to being transparent with our data for a Duchenne community in need of new treatment options that can meaningfully impact disease. In addition, we are encouraged by the safety data at both dose levels and initial caregiver observations of strength and motor function improvement in boys treated with RGX-202. We look forward to following these patients to establish durability and greater separation from baseline, which we hope will further establish RGX-202 as an important option among treatments in development."
"There is a need for treatment options for boys with Duchenne that have the potential to alter the disease trajectory," said Aravindhan Veerapandiyan, M.D., Arkansas Children's Hospital. "I am very pleased with the new microdystrophin expression data from RGX-202 dose level 2. It is encouraging to see that patients are safely progressing through their trial protocol strength and motor function assessments with early observations of improvement, including in older boys."
Safety Update
As of February 28, 2024, RGX-202 has been well tolerated with no drug-related serious adverse events in five patients, aged 4.4 to 12.1 at dose level 1 (1x1014 genome copies (GC)/kg body weight) and dose level 2 (2x1014 GC/kg body weight). Time of post-administration follow up ranges from approximately seven weeks to over eleven months. All patients who reached three-month follow-up have completed the immunosuppression regimen per study protocol.
Biomarker Data and Recorded Strength and Functional Observations
In new data from the first patient, aged 12.1 years, who received RGX-202 at dose level 2, RGX-202 microdystrophin expression was measured to be
All four patients, across both dose levels, who completed three-month trial assessments indicate encouraging increases in expression of RGX-202 microdystrophin and reduction from baseline in serum CK levels, supporting evidence of clinical improvement.
RGX-202 microdystrophin levels were measured using an automated and precise western blot method (Jess), and comparable results were confirmed with a proprietary liquid chromatography-mass spectrometry (LC-MS) method. Elevated CK levels are associated with muscle injury and are uniformly elevated in patients with Duchenne. Among patients aged 8 to 11 years old at screening, RGX-202 microdsytrophin expression levels (change from baseline) at three months following RGX-202 administration was higher in dose level 2. The patient data is presented below.
Patient | Age at Dosing | Weight at | Western blot (Jess method), | CK Levels, | |
Dose level 1 | 1 | 4.4 | 17.8 | 38.8 | -43 |
2 | 10.5 | 28.3 | 11.1 | -44 | |
3 | 6.6 | 26.8 | 83.4 | -93 | |
Dose level 2 | 4 | 12.1 | 24.3 | 75.7 | -77 |
Dose Comparison of RGX-202 Microdystrophin Expression Levels in Older Boys
Dose level 1 | Dose level 2 | |
Ages > 8 years | 11.1 | 75.7 |
In addition, new recordings of the AFFINITY DUCHENNE trial clinic assessments and home videos shared with trial investigators by caregivers illustrate patients treated with RGX-202 are demonstrating initial evidence of strength and functional improvement.
"Several of the items in the clinic recordings are timed tasks and they are also measured on the NSAA. We plan to present strength and functional assessment data for both dose levels from the trial later this year, but today this is a glimpse of how these boys are gaining functional skills since dosing," said Dr. Veerapandiyan, "The montage of home videos provides some insight into a family's experience with RGX-202. Being able to do these activities, which can be quite difficult for boys with Duchenne, is informal, but a set of important observations of their experience."
Clinical Program Updates
REGENXBIO expects to make a pivotal dose determination in mid-2024. The Company also expects to share strength and functional assessment data for both dose levels and the initiation of a pivotal trial in the second half of 2024. The Company plans to use RGX-202 microdystrophin expression as a surrogate endpoint to support a Biologics License Application (BLA) filing using the accelerated approval pathway.
Conference Call Details
REGENXBIO will host a webcast Tuesday, March 5 at 8:30 a.m. ET. The live webcast can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
AFFINITY DUCHENNE Trial Design
The Phase I/II AFFINITY DUCHENNE trial is a multicenter, open-label dose escalation and dose expansion clinical study to evaluate the safety, tolerability and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in patients with Duchenne. In the dose evaluation phase of the trial, four ambulatory, pediatric patients (ages 4 to 11 years old) are expected to enroll in two cohorts with doses of 1x1014 GC/kg body weight (n=2) and 2x1014 GC/kg body weight (n=2). After an independent safety data review for each cohort, a dose expansion phase of the trial may allow for additional patients to be enrolled.
The trial design was informed by the Duchenne community and engagement with key opinion leaders, including a comprehensive, short-term, prophylactic immunosuppression regimen to proactively mitigate potential complement-mediated immunologic responses, and inclusion criteria based on dystrophin gene mutation status, including DMD gene mutations in exons 18 and above. Trial endpoints include safety, immunogenicity assessments, pharmacodynamic and pharmacokinetic measures of RGX-202, including microdystrophin protein levels in muscle, and strength and functional assessments, including the North Star Ambulatory Assessment (NSAA) and timed function tests.
About RGX-202
RGX-202 has differentiated and important biology most similar to naturally occurring dystrophin that protects from the muscle degradation associated with Duchenne. RGX-202 is designed to deliver a transgene for a novel microdystrophin that includes the functional elements of the C-Terminal (CT) domain found in naturally occurring dystrophin. Presence of the CT domain has been shown in preclinical studies to recruit several key proteins to the muscle cell membrane, leading to improved muscle resistance to contraction-induced muscle damage in dystrophic mice. Additional design features, including codon optimization and reduction of CpG content, may potentially improve gene expression, increase translational efficiency and reduce immunogenicity. RGX-202 is designed to support the delivery and targeted expression of genes throughout skeletal and heart muscle using the NAV AAV8 vector, a vector used in numerous clinical trials, and a well-characterized muscle-specific promoter (Spc5-12).
About Duchenne Muscular Dystrophy
Duchenne is a severe, progressive, degenerative muscle disease, affecting 1 in 3,500 to 5,000 boys born each year worldwide. Duchenne is caused by mutations in the Duchenne gene which encodes for dystrophin, a protein involved in muscle cell structure and signaling pathways. Without dystrophin, muscles throughout the body degenerate and become weak, eventually leading to loss of movement and independence, required support for breathing, cardiomyopathy and premature death.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.
FORWARD-LOOKING STATEMENTS
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's future operations, clinical trials, costs and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2023, and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the
Zolgensma® is a registered trademark of Novartis Gene Therapies. All other trademarks referenced herein are registered trademarks of REGENXBIO.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-new-positive-initial-efficacy-data-from-affinity-duchenne-trial-302079525.html
SOURCE REGENXBIO Inc.
FAQ
What is the purpose of the Phase I/II AFFINITY DUCHENNE trial?
What were the key findings from the trial?
What age group does the trial focus on?
What is the significance of the microdystrophin expression data from dose level 2?
What safety updates were provided in the PR?
When does REGENXBIO plan to initiate a pivotal trial?
What endpoints are included in the trial design?
Where can the webcast of the company's presentation be accessed?
